Abstract: In a food-like medicine comprising a seamless capsule enclosing effective ingredients and at least one of a gel and a high viscous liquid, the seamless capsule has: a diameter (d) within a range of 0.5-5 mm, a relation of a membrane thickness (.theta.) of the seamless capsule to the diameter (d) being 0.01 d.ltoreq..theta..ltoreq.0.05 d, and a ratio (.rho.) of a major axis to a minor axis of the seamless capsule not more than 1.3.

Abstract: Nanosols and process for preparing the same allow colloidally dispersed solutions of scarcely water-soluble active substances to be stabilized with gelatin or its derivatives, by partly or fully setting the iso-ionic point (IIP, equivalent to a neutral charge) between the gelatin and the surface charged active substance particles. In order to neutralize the charge of the system composed of active substance particles and gelatin, the surface charge of the particles is compensated by a corresponding opposite charge of the gelatin molecules. For that purpose, a determined charge in relation to the isoelectric point (IEP) and the pH value of the solution is set on the gelatin molecules. By stabilizing in this way the practically monodispersed state thus generated, the Ostwald maturation of the colloidal particles of scarcely soluble active substance is strongly reduced.

Abstract: An improved method of treating psoriasis involves controlling the enhanced proliferation and terminal differentiation of psoriatic epidermis through the activity of epidermal phosphorylase kinase. In general, the method involves contacting psoriatic epidermal cells with a combination of substances affecting the activity of phosphorylase kinase. The combination can be: (1) a calmodulin inhibitor together with a stimulator of cAMP-dependent protein kinase II, (2) a calmodulin inhibitor together with a calcium channel blocker; (3) a stimulator of cAMP-dependent protein kinase II together with a calcium channel blocker; or (4) a calmodulin inhibitor together with a calcium channel blocker and a stimulator of cAMP-dependent protein kinase II. Alternatively, a selective phosphorylase kinase inhibitor such as curcumin can be administered, alone or with an agent such as vitamin D.sub.3 or an analogue thereof, etretinate, diltiazem, or anthralin. The invention also includes pharmaceutical compositions.

Abstract: This invention provides an antioxidant-containing effervescent composition comprising, as essential components, 0.05 to 15% by weight of an antioxidant-containing powder, 10 to 35% by weight of sodium hydrogencarbonate and/or sodium carbonate, 10 to 70% by weight of a neutralizing agent and 30 to 55% by weight of an excipient. The antioxidant-containing effervescent composition of the invention stably contains an antioxidant and is excellent in solubility.

Abstract: Soft gelatin capsules consisting of capsule shell and capsule filling, where the capsule filling comprises one or more water-insoluble active ingredients) in the form of a powdered product.

Abstract: To increase the solubility of acidic medicines a high concentration solvent system to be encapsulated comprisesa) 10-80% by weight acidic medicine,b) 0.1-1.0 mole hydroxide ions for one mole equivalent of said medicine, andc) 1-20% by weight water.included in polyoxyethylene sorbitan fatty acid ester as the solvent.

Abstract: A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.

Abstract: An essentially herbal or herbal extract composition for the treatment and control of breath odors and aiding digestion, and method of treatment or control of breath odors and aiding digestion therewith. The preferred composition contains ginger, licorice, chamomile, parsley seed oil, and sunflower seed oil in a delivery system which is intended to be ingested and swallowed whole for delivery of the ingredients to the stomach and/or lower in the digestive tract.

Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.

Abstract: An oral administration carbamazepine medicament with a retarded active substance release is disclosed. An aqueous plasticised polymer dispersion is applied on carbamazepine crystals without causing formation of carbamazepine dihydrate. The carbamazepine crystals with their aqueous coating may be mixed with appropriate auxiliarly substances, shaped into divisible tablets or filled into capsules.

Abstract: A pharmaceutical product in the form of a gelatin capsule with a fill comprises a hydrogel material, a gas generator and an oil-based or hydrophilic based liquid vehicle, wherein upon contact with acidic aqueous medium the gelatin capsule breaks up, disperses or dissolves and the fill reacts to form a foam.

Abstract: Disclosed is a method of treatment of steroid requiring inflammatory diseases using certain saturated monocyclic and bicyclic terpene compounds. These compounds may be administered in the form of capsules resistant to gastric juice, infusion solutions or intramuscular injection solutions. Because these particular terpene compounds exhibit steroid-like effects but without the harmful side-effects of conventional corticosteroids, the use of corticosteroids is substantially reduced, and in some cases, completely eliminated. Therefore, these terpene compounds are also suitable for long-term therapy and prophylaxis.

Abstract: A composition comprising at least one non-steroidal antiinflammatory drug, their salts, their chirally pure forms, isomers and derivatives, analogues and adducts thereof and two drugs pitofenone hydrochloride and fenpiverinium bromide in a pharmaceutically acceptable combination.

Abstract: Disclosed is a method of reducing crosslinking in gelatin capsules wherein an amino acid and a carboxylic acid are incorporated into the capsule fill, as well as filled gelatin capsules that utilize the disclosed method. The inventive method is especially useful for pharmaceutical formulations which include hydrochlorothiazide, triamterene, gemfibrozil, chloramphenicol, etodolac, piroxicam, nifedipine, tetracycline, diphenhydramine, hydroflumethiazide and rifampin, or a combination thereof as active ingredient.

Abstract: The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Abstract: An insecticidal composition in the form of an aerosol water-in-oil emulsion is disclosed which comprises:(a) an amount of an aqueous suspension of microencapsulated insecticide to give an insecticide concentration in the composition of from 0.001 to 5% w/w;(b) one or more solvents in an amount of from 1 to 20% w/w;(c) one or more emulsifiers in an amount of from 0.2 to 10% w/w and selected from the group comprising mono-, di-and tri-sorbitan esters, polyoxyethylene sorbitan esters, mono- and poly-glycerol esters, ethoxylated nonionic emulsifiers, propoxylated nonionic emulsifiers and ethoxylated/propoxylated nonionic emulsifiers;(d) from 2 to 80% w/w of one or more propellants;(e) optionally from 0.001 to 5% w/w of one or more oil phase soluble insecticides; and(f) the balance being water.

Abstract: Methods for reestablishing normal nocturnal growth hormone and prolactin secretion in adults with low slow-wave (deep) sleep are provided. In particular, methods are disclosed where .gamma.-hydroxybutyrate is orally administered to subjects just prior to retiring.

Abstract: The present invention relates to a new form of biocompatible materials (e.g., lipids, polycations, polysaccharides) which are capable of undergoing free radical polymerization, e.g., by using certain sources of light; methods of modifying certain synthetic and naturally occurring biocompatible materials to make polymerizable microcapsules containing biological material coated with said polymerizable materials, composites of said polymerizable materials, methods of making microcapsules and encapsulating biological materials therein, and apparatus for making microcapsules containing biological cells (particularly islets of Langerhans) coated with polymerizable alginate or with a composite thereof (e.g., alginate and PEG). The present invention also relates to drug delivery systems relating to the foregoing, as well as bioadhesives and wound dressings made utilizing the foregoing technology.

Abstract: Improved oral cyclosporin formulations which have high bioavailability and are capable of administration in hard capsules, are provided. In the subject formulations, cyclosporin is delivered in an orally acceptable vehicle comprising at least one alkanol of from 2 to 3 carbon atoms in combination with at least one non-ionic surfactant and an ester of an alcohol and a fatty acid having a hydrocarbon chain of from 14 to 18 carbon atoms. The subject formulations find use in immunosuppressive therapy.

Abstract: Soluble fenofibrate (Rec. INN) formulations exhibiting a significantly improved bioavailability after oral administration ("superbioavailability"), a process for their production and medicaments comprising these formulations. The said fenofibrate pharmaceutical dosage formulations essentially contain fenofibrate in solution in a solubilizing agent consisting of a non-ionic surfactant, diethylene glycol monoethyl ether (DGME).

Abstract: The present invention is directed to a fluid-imbibing drug delivery device which is useful for the initial delayed delivery of an active agent formulation to a fluid environment of use, the initial delay period to startup or activation being of a predetermined length of time. The dispensing device is formed of a first and second housing that are in reversibly sliding telescoping arrangement with each other. The first housing contains the active agent formulation and has an aspect ratio less than 1. The housings are preferably. ovoloid in shape.

Abstract: A pharmaceutical formulation comprising an amoxycillin hydrate and an effervescent couple, for example citric acid plus sodium bicarbonate or sodium glycine carbonate, or tartaric acid or malic acid plus sodium carbonate. Potassium equivalents of these sodium salts may be used. The formulations may be free flowing powders or granules, or tablets.

Abstract: This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.

Abstract: Encapsulated small articles such as medicines in caplet or cylindrical form are disclosed. Gelatin half capsules are formed on the pins of pin blocks and are delivered to a station at which they are trimmed and fitted over the opposite ends of the product to be encapsulated. The capsule halves are first dried to a condition in which they have about 20 wt. % moisture and are thereafter press fitted over the ends of the caplets and allowed to dry to shrink fit tightly onto the caplets making it virtually impossible to remove them from their gelatin coverings without leaving visible evidence of tampering. The finished product has a smoother outer surface which lends itself to overprinting with a precise color separation line between the two capsule halves if the capsule halves are distinctly differently colored.

Abstract: Microcapsules based on crosslinked plant polyphenols are described. These microcapsules are obtained by the interfacial crosslinking of plant polyphenols, particularly flavonoids. When incorporated in a composition such as a cosmetic, pharmaceutical, dietetic or food composition, these microcapsules make it possible to prevent any impairment of this composition, in particular any color modification, while at the same time preserving the activity, especially the anti-free radical and/or antioxidizing activity, of the plant polyphenols, particularly the flavonoids.

Abstract: The invention relates to water-emulsifiable granules of crop protection agents composed of the pesticidal active substance in liquid or dissolved form and an at least partially water-soluble shell-forming structural material, to the use of these granules as novel, advantageous formulations of crop protection agents, and to processes for their preparation. It furthermore relates to the general use of polyvinyl alcohols as shell-forming structural materials in the preparation of water-emulsifiable granules which contain organic compounds dissolved in a high-boiling solvent or solvent mixture.

Abstract: Fragrances in soft gelatin capsules are disclosed. The desired fragrance is dissolved in a solvent system comprising a volatile solvent, a non-volatile cosolvent, or a combination of a volatile solvent and a non-volatile cosolvent or cosolvents. The resulting solution is then encapsulated by soft gelatin shell prepared with an odor-free, glycerol free gelatin plasticized with a partially dehydrated, hydrogenated glucose syrup.

Abstract: A method of repelling soil borne pests, nematodes, insects and insect larvae includes applying a solution of naphthalene or precipitated flocculent naphthalene into or upon the soil where the naphthalene volatilizes and repels nematodes and soil pathogens. In another embodiment of the invention, micron size particles of naphthalene are encapsulated in a polymer which is injected into or applied to the surface of the soil. In a further embodiment of the invention, micron-sized particles of naphthalene are attached to a carrier strip which is applied to the surface of the soil as a mulch, applied below the surface of the soil, or attached to trees or plants for repelling pests.

Abstract: An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, skim milk, curd, whey, the milk mucin complex, the 46 Kd app.MW glycoprotein, a polypeptide having an amino acid sequence having the rotavirus binding specificity of the 46 Kd app.MW HMFG glycoprotein or mixtures thereof. An anti-diarrheal kit comprises the anti-rotaviral agent of this invention and instructions for its use, and optionally a foodstuff. A method for inhibiting or countering rotavirus infection in mammalian cells comprises contacting the cells with an anti-rotaviral amount of the agent of this invention.

Abstract: A method for combatting cellulitis or reducing localized fatty excesses involves administering a body slimming amount of a composition which contains, as the sole slimming agent, an .alpha.-tocopherol, benzyl, xanthinol or hexyl nicotinate, or .alpha.-tocopherol acetate.

Abstract: A method for encapsulating biological substances in biocompatible microcapsules is disclosed, the method comprising:(a) maintaining a coating-forming liquid film sheet transverse to a vertical plane, said sheet comprising an organic polymerizable monomer liquid,(b) causing droplets comprising biological substances in an aqueous medium to fall downwardly through said liquid film sheet to form microcapsules comprising cores of said droplets coated by said film,(c) permitting said microcapsules to fall downwardly from said liquid film sheet, and(d) polymerizing said liquid film coatings during descent of said microcapsules below said sheet to form a permeable polymer coating of a sufficient structural integrity so that said microcapsules are self-supporting.

Abstract: Capsules (such as hard gelatin, cellulose and plastic capsules) containing pharmaceutical powders which are administered to a patient via inhalation are treated so as to increase the effective amount of the pharmaceutical agent reaching the respiratory system of the patient. The capsules are coated internally with a lubricant during manufacture and in one aspect, the method involves exposing the lubricant-coated inner surface of the capsule to a pharmaceutically acceptable solvent which dissolves the lubricant. Generally, the solvent is volatile, and bactericidal (e.g. ethanol). The pharmaceutical powder is inserted in the capsule following this washing procedure. Alternatively, the lubricant-coated capsule is dusted internally with a dusting agent such as a salt (e.g. sodium chloride) or a sugar (e.g. lactose, mannitol, trehalose or sucrose) prior to inserting the pharmaceutical powder inside the capsule.

Abstract: The present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a cosurfactant, oil and a surfactant which is suitable for the formulation of a soft capsule for oral administration, said cyclosporin, dimethyl isosorbide, oil and surfactant being present in the ratio of 1:1-5:1-5:2-10, and preferably in the ratio of 1:2-4:2-5:2-4:7, by weight. Since dimethylisosorbide has substantially no membrane permeation property, the soft capsule preparation according to the present invention is outstandingly stable in comparison with the soft capsules containing ethanol, propylene glycol, transcutol, glycofurol, etc., as a cosurfactant in the prior art, and further provides an advantage in that the pharmaceutical effect, appearance and composition content of the soft capsule according to the present invention are not changed.

Abstract: The invention provides oral controlled-release preparations suitable to deliver drugs to different sites of gastrointestinal tract and suitable to control the release rate of drugs. As a first function, targeting of drugs to the lower part of the small intestine or colon is possible with two technologies. One is a time-controlled release system comprising adjusting the balance of the tolerability and thickness of a water-insoluble material membrane and the amount of a swellable substance. The other one is an intestinal pressure controlled-release system comprising adjusting the thickness of a water-insoluble material membrane. As a second function, by adjusting pore number, pore size and the amount of gel-forming substance, a sustained-release preparation of extremely water-soluble, hydrophilic, low-molecular weight drug is possible.

Abstract: Rapid-release S(+)-ibuprofen pellets are proposed whose bioavailability is comparable to that of commercially available racemate formulations. The rapid release of the active substance is promoted by using small amounts of basic inorganic salts, preferably sodium carbonate, or dilute alkali metal hydroxide solutions. Pellets with an active substance content of 90-99% by weight are obtainable in this way. The pellets are suitable for the application of coatings. Pellets with a protective coating can be compressed directly to tablets in this form and with small amounts of suitable tableting adjuncts. The use of the pharmacologically active S(+)-ibuprofen and of the small amounts of adjuncts required makes it possible to prepare compact pharmaceutical forms.

Abstract: A gelatin capsule that is generally resistant to humidity having a non-hygroscopic plasticizer and an elasticity reducing gelatin extender in the formulation of the gelatin capsule shell. The capsule is capable of being manufactured on conventional rotary die encapsulation devices and can readily hold liquid fill materials. The capsule is breakable with manual pressure.

Abstract: Prolamine fractions of grain proteins, applied as a single coating in weight ratios of 5 to 100% relative to the active substance being coated, result in the production of a liquid suspension which effectively masks the taste of orally administered drugs which often are extremely bitter. The taste masking is stable over prolonged periods of storage time of the suspension. The prolamine coating does not restrict the immediate bioavailability of the active substance. Prolamine coating is effective in masking the taste of antibiotics, vitamins, dietary fiber, analgesics, enzymes and hormones. Zein, gliadin or a mixture thereof, particularly in combination with between 2.

Abstract: This invention relates to an etoposide preparation containing an etoposide composition comprising an etoposide, polyvinylpyrrolidone, and water-soluble cellulose ether derivative wherein the proportion of the respective components is about 0.25 to 2 parts by weight for polyvinylpyrrolidone and about 0.0028 to 0.2 parts by weight for the water-soluble cellulose ether derivative per 1 part by weight of the etoposide, and about 10 to 20% (w/w) for the etoposide in the whole amount of the composition.

Abstract: A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

Abstract: The drug consists of a two-part gelatine capsule filled with a non-toxic substance, low on burnable ingrediants, which enlarges its volume when set free in the stomach. The filling can be dissolved within the digestive tract of the human body, e.g. compressed cellulose. The person taking the drug experiences through the volume enlargement in the stomach for a certain time a feeling of fulness, hencely making it easier to lose weight.

Abstract: This invention relates to a soft-shelled gelatin capsule which contains particles in a liquid vehicle.

Abstract: An alstonine composition is useful as a selective marker of tumor cells and/or of chromosomal aberrations, and for the detection thereof by measurement of fluorescence at about 375 nm. Thus, an alstonine preparation can be used as a diagnostic agent designed for selective detection of tumoral diseases, and in cytogenetics. The diagnostic agent has application in preoperative, peroperative and postoperative diagnoses.

Abstract: The invention relates to a process for the preparation of therapeutically useful, highly stable soft gelatine capsules containing native oils obtained in the case of vegetable oils by the cold pressing of mainly plant parts, such as seeds, which comprises adjusting the free fatty acid content of the oil to an acid number of from about 0.3 to about 4.5 by mixing oils of identical or different natural source with a different acid number not in excess of about 4.5 and then filling the oil into soft gelatine capsules aromatized from about 0% to about 10% by mass of a perfume.

Abstract: A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

Abstract: A gelatin capsule sheath in which a portion of the gelatin is replaced with a high amylose content starch to provide a dry capsule sheath having 3-60% by weight high amylose starch wherein the amylose content of the starch is at least 50% and preferably 90% high amylose starch. The capsules of this invention have textured frosted or satin finish which do not stick together, form strong seals, are resistant to changes in shape, and are more economical to manufacture.

Abstract: An ibuprofen-containing medicament which contains ibuprofen only in the (S)-(+)-form is disclosed. (S)-(+)-ibuprofen is more than twice as active as the racemate which has until now been used in the treatment of rheumatism. This permits reduction of the quantity of active ingredient and the size of the tablets or dragees.

Abstract: The invention provides a pharmaceutical composition for treating performance anxiety and social phobia comprising a therapeutic amount for the treatment of a patient of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound. The preferred .beta.-adrenergic receptor blocking compound is the lipophilic .beta.-blocker propranolol HCL. The anti-diaphoretic compound of the present invention is preferably glycopyrrolate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating performance anxiety or social phobia in a patient comprising administering the composition of the invention to a patient in need of such treatment is also provided. The composition administered in the present method comprises a therapeutic amount of a .beta.-adrenergic receptor blocking compound and an anti-diaphoretic compound.

Abstract: An ibuprofen-containing medicament which contains ibuprofen only in the (S)-(+)-form is disclosed. (S)-(+)ibuprofen is more than twice as active as the racemate which has until now been used in the treatment of rheumatism. This permits reduction of the quantity of active ingredient and the size of the tablets or dragees.

Abstract: A pharmaceutical composition comprising a shaped enteric material having distributed therethrough preferably substantially uniformly, pharmaceutical loaded particles, said particles having a size no greater than about 10 microns in any dimension and being alkali insoluble and the method of delivering pharmaceuticals to Peyer's glands.

Abstract: A process for reducing precipitation of difficultly soluble pharmaceutical active in a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol.